




Update on SNMMI Activities
including
Radiopharmaceutical Therapy
and **Dosimetry**
Richard L. Wahl


Updated: May 2022





SNMMI's History

- Founded in 1954
- The largest international scientific organization dedicated to nuclear medicine and radionuclide therapy
- A multidisciplinary organization
 - More than 14,000 physicians, scientists, pharmacists and technologists
 - Industry partners interested in the diagnostic, therapeutic and investigational uses of molecular imaging and therapy agents, instrumentation and techniques



SNMMI Leadership



Richard Wahl, MD



Munir Ghesani, MD



Helen Nadel, MD




Dusty York, MAEd



Krystle Glasgow, MIS

Organizational Structure



SNMMI Membership

SNMMI has +/- 15,000 members!




Chart above does NOT include free trial resident/student members.



SNMMI Value Initiative

Updates and 2022 Priorities

Advancing the critical role of nuclear medicine, molecular imaging, and radiopharmaceutical therapy.

Value Initiative Leadership

SNMMI is honored to have the following distinguished physicians and scientists serving on the Value Initiative Board:

Chair: Satoshi Minoshima, MD, PhD, Univ. of Utah (SNMMI Past President)

- Domain 1 ▪ Quality of Practice: **Heather Jacene, MD**, Dana Farber Cancer Institute
- Domain 2 ▪ Research & Discovery: **John Sunderland, PhD**, Univ. of Iowa
- Domain 3 ▪ Workforce Pipeline & Life-Long Learning: **Christopher Palestro, MD**, Zucker School of Medicine at Hofstra/Northwell
- Domain 4 ▪ Advocacy: **Cathy Cutler, PhD**, Brookhaven National Laboratory (SNMMI Secretary/Treasurer)
- Domain 5 ▪ Outreach: **Giuseppe Esposito, MD**, Georgetown Univ. Hospital
- Domain 6 ▪ Organizational Strength & Stability: The SNMMI Board as a whole are responsible for this domain

Value Initiative Industry Alliance



The **SNMMI Value Initiative Industry Alliance** is a forum for industry to work in partnership with SNMMI to build the future of nuclear medicine, molecular imaging, and radiopharmaceutical therapy through funding support, strategic industry guidance, and collaborative knowledge sharing.

36 companies...and growing!





Value Initiative Industry Alliance Leadership

SNMMI is honored to have the following distinguished corporate leaders serving on the Value Initiative Industry Alliance Advisory Committee (Leadership Circle) in 2022:

Co-Chair (2022): *Matt Shah, VP Global Sales & Marketing, Siemens Molecular Imaging*

Co-Chair (2022): *Terri Wilson, President, Blue Earth Diagnostics*

- *Mike Rossi, General Manager, US, Advanced Accelerator Applications, a Novartis Company*
- *Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen*
- *Yvette Walker-Jones, MPH, Associate Director, Key Medical Expert Engagement, US Alzheimer's Disease Marketing, Biogen*
- *Michael Pintek, President, Nuclear & Precision Health Solutions, Cardinal Health*
- *Teresa Cronin, Director, Corporate Advocacy, Eisai*
- *Martina Herrmann, Head of Global Medical Affairs, ITM*
- *James Kaufman, VP, Marketing, Jubilant DraxImage, Inc.*
- *Huw Jones, Vice President of Commercial, Lantheus/Progenics*

*Thank!
You!*

SNMMI Value Initiative Industry Alliance
Thank you for continued support and partnerships



SNMMI Value Initiative Domains

Quality of Practice

Research & Discovery

Workforce Pipeline & Lifelong Learning

Outreach

Advocacy



SNMMI Value Initiative Domains

Quality of Practice

Research & Discovery

Workforce Pipeline & Lifelong Learning

Outreach

Advocacy



Quality of Practice

Ensuring SNMMI members are known for high-quality, value-driven performance, and delivery of patient-centered nuclear medicine practice. To achieve the high-quality desired health outcomes, SNMMI will continue to pave way for the delivery of efficient, effective and patient-centered nuclear medicine practice by its members.



Quality of Practice 2021-2022 Priorities

1

Increase the development and dissemination of clinical guidance documents, including appropriate use criteria

2

Ensure the development of value/quality metrics for nuclear medicine

3

Standardize best practices to enhance operational efficiency

4

Expand continuing education options for practitioners



New Appropriate Use Criteria

Completed the AUC for **PSMA PET imaging** and **Musculoskeletal Infection Imaging**; both were published in JNM.

Alzheimer's Disease AUC Revision

Currently in peer review. This updated AUC, developed in conjunction with the **Alzheimer's Association**, includes tau imaging and imaging for management of disease-modifying therapy.

Increase the development and dissemination of clinical guidance documents, including appropriate use criteria.

Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging

PET Imaging

Hossein Jadvar¹, Aereim Calais², Stefano Fanti³, Felix Feng⁴, Kirsten L. Greene⁵, James L. Gulley⁶, Michael Hofman⁷, Bridget F. Kooztz⁸, Daniel W. Lin⁹, Michael J. Morris¹⁰, Steve P. Rowe¹¹, Trevor J. Royce¹², Simpa Salami¹³, Bilal Savir-Baruch¹⁴, Sandy Srinivasan¹⁵, Thomas A. Hopst¹⁶

¹Department of Radiology, University of Southern California, Los Angeles, CA, USA
²Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA

³University of Bologna, Bologna, Italy

⁴Department of Radiation

⁵Department of Urology, U

⁶National Institutes of He

⁷Molecular Imaging and T

⁸Melbourne, Victoria, Aust

⁹Melbourne, Melbourne, V

¹⁰Department of Radiology

¹¹Department of Urology, U

¹²Memorial Sloan Ketterin

¹³Department of Radiology

¹⁴Department of Radiology


¹⁵Department of Urology,

¹⁶Department of Radiology

¹⁷Department of Medicine

¹⁸Department of Radiology

¹⁹CA, USA



Standardize best practices to enhance operational efficiency



Procedure Standard Development

In conjunction with ACR and EANM continues.

Upcoming procedure standards include:

- Imaging with ¹⁸F-FES
- **Use of ¹⁷⁷Lu-PSMA Therapies**
- SSTR PET (including ⁶⁴Cu-dotatate, ⁶⁸Ga-dotatate, and ⁶⁸Ga-dotatoc)

**All new and updated procedure standards will have a statement about appropriate agent administration and a template report language.*



Procedure Standards Development

Standardize best practices to
enhance operational efficiency

Approved and available on SNMMI's website:

- Joint SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine **Evaluation and Therapy of Differentiated Thyroid Cancer**
- SNMMI Procedure Standard/EANM Practice Guideline for **Molecular Breast Imaging with Dedicated Gamma-Cameras**
- Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for **imaging of pediatric gliomas** using PET with radiolabeled amino acids and ^{18}F -FDG: version 1.0.
- **^{18}F -FDG PET/CT Used During Immunomodulatory Treatments** in Solid Tumors



**All new and updated procedure standards will have a statement about appropriate agent administration and a template report language.*



Coming Soon: Reader Training

at the SNMMI 2023 Mid-Winter Meeting

- Nuts and Bolts sessions on new nuclear medicine and molecular imaging agents

Expand continuing education
options for practitioners



SNMMI 2023 Mid-Winter Meeting
January 26-28, 2023
Hyatt Regency | San Francisco, CA



SNMMI Value Initiative Domains

Quality of Practice

Research & Discovery

Workforce Pipeline & Lifelong Learning

Outreach

Advocacy



Research & Discovery

Ensuring SNMMI advances the development and approval of nuclear medicine and molecular imaging technologies, including therapies. Realizing that innovation is essential for our field, our science should promote and encourage these advancements. Sufficient funding is an overarching issue for research, and we will strive to increase funding from a variety of sources.



Research & Discovery

2021-2022 Priorities

1

Encourage and promote research in the field

2

Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics, and instrumentation

3

Improve the quality of nuclear medicine trials and literature

4

Enhance research on how artificial intelligence, machine-learning, and deep learning can be applied to nuclear medicine and molecular imaging.


5

Develop and organize resources (with Outreach) to help hospitals implement theranostics, including guidelines on physical space, personnel, dose handling, dosimetry, patient discharge

Radiopharmaceutical Therapy (RPT) Strategic Plan

Performing radiopharmaceutical therapies is becoming more complex and requires more facilities, resources, experience and training than imaging alone.

Maintaining and growing the SNMMI's role as the thought, scientific and practice leader in this area is the strongly supported.



Radiopharmaceutical Therapy (RPT) Strategic Plan

Goals:

- Ensure adequate Reimbursement for RPTs and Dosimetry
- Develop processes and standards for performing dosimetric measurement of RPT in research and clinical settings (Dosimetry Task Force)
- Provide appropriate education and training for NM practitioners without RPT experience and residents/fellows, CE for current NM physicians
- Therapy Web Portal (therapy.snmmi.org) for all RPT information
- Establish a RPT Registry (RaPTR) to collect both image and clinical data
- Initiate a Radiopharmaceutical Therapy Centers of Excellence program to recognize facilities that provide excellence in RPT

Therapy Standardization and Clinical Education



Highlights include:

- Mock Tumor Board session
- Sessions on Operational Issues, Dosimetry, MIBG, Prostate, Neuroendocrine, Thyroid, and Leukemia/Lymphoma cancers
- Over 211 attendees and 40 exhibitors

The SNMMI Radiopharmaceutical Therapy Central Website


- Launched in late 2020
- Dedicated repository for all SNMMI radiopharmaceutical therapy related educational content and resources

www.snmmi.org/Therapy



The SNMMI Radiopharmaceutical Therapy Central Website includes:

- Educational Content
 - Including on-demand meeting content, webinars, and JNM articles
- Guidelines for Therapies
 - including procedure standards for therapy, and applicable AUC.
- Tools for Technologists
- Patient Resources



www.snmmi.org/Therapy

Dosimetry Task Force

Lu-177 Dosimetry Challenge 2021

Dosimetry Challenge results published in 5 forthcoming papers:

- General results – software used, variability in planar and SPECT
- Segmentation with recommendations on how to and reporting
- Time activity curves
- Variability when all components provided (Task 5)
- Model of the areas of variability and those with the largest impact

- **Webinar:** Overview of the Lu-177 Challenge

➤ Thursday May 5 @ 4pm ETD

Carlos Uribe, PhD

- **Hands on Dosimetry Open House:**

Dosimetry software vendors will have their software available to a 'test drive'

➤ Monday June 13 @ 6:00-7:45 am

- **CE10:** Nuts and Bolts - Dosimetry and Case Studies

➤ Saturday June 11 @ 3:15 pm

Dosimetry Task Force



- Dosimetry Task Force supplement to JNM was published in December 2021
- Exceptionally strong interest in the supplement to date.
- Accessed over 12,000 times with each article accessed 1,500 on average.
- Social media engagement is also high
- Commercial support was exceptional and represents the fields' interest in dosimetry



Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice

Richard L. Wahl¹ and John Sunderland²

¹Mallinckrodt Institute of Radiology, St. Louis, Missouri; and ²University of Iowa, Iowa City, Iowa



Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources

Jacek Capala¹, Stephen A. Graves², Aaron Scott³, George Sgouros³, Sara St. James⁴, Pat Zanzonico⁵, and Brian E. Zimmerman⁶



Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns

George Sgouros¹, Yuni K. Dewaraja², Freddy Escorcia³, Stephen A. Graves⁴, Thomas A. Hope⁵, Amir Iravani⁶, Neeta Pandit-Taskar⁷, Babak Saboury⁸, Sara St. James⁵, and Pat B. Zanzonico⁹



Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Richard L. Wahl¹, George Sgouros², Amir Iravani¹, Heather Jacene³, Daniel Pryma⁴, Babak Saboury⁵, Jacek Capala⁵, and Stephen A. Graves⁶



Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice

Neeta Pandit-Taskar¹, Amir Iravani², Dan Lee³, Heather Jacene⁴, Dan Pryma⁵, Thomas Hope⁶, Babak Saboury⁷, Jacek Capala⁷, and Richard L. Wahl²



Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities

Stephen A. Graves¹, Alexandru Bageac², James R. Crowley³, and Denise A.M. Merlino⁴



Dosimetry for Radiopharmaceutical Therapy: The European Perspective

Michael Lassmann¹, Uta Eberlein¹, Jonathan Gear², Mark Konijnenberg³, and Jolanta Kunikowska⁴



An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge

Carlos Uribe^{1,2}, Avery Peterson³, Benjamin Van³, Roberto Fedrigo⁴, Jake Carlson⁵, John Sunderland⁶, Eric Frey^{*7,8}, and Yuni K. Dewaraja^{*3}

Lu-177 Dosimetry Challenge 2021

Under review!
Results coming
soon!


Designed to measure the variability of the major steps involved in dosimetry calculation

Participant will get two datasets to use in calculations. Elements are provided incrementally in a series of stages

OPEN to all: individuals, institutions, and industry

For more information:

www.snmmi.org/DosimetryChallenge



Radiopharmaceutical Therapy Centers of Excellence

SNMMI.ORG HOME EDUCATION RESOURCES 2022 THERAPEUTICS CONFERENCE ABOUT SNMMI

SNMMI Radiopharmaceutical Therapy Centers of Excellence

Radiopharmaceutical Therapy Centers of Excellence

SNMMI designated Centers of Excellence in Radiopharmaceutical Therapy meet strict regulatory, training, qualification, experience, and performance criteria to help assure patients, their families, referring physicians, and payors that rigorous procedures are in place and followed, leading to appropriate patient selection and outcomes from radiopharmaceutical therapy.

Educational Resources

Explore research articles and continuing education for radiopharmaceutical therapies, including recorded content from SNMMI meetings and webinars: [More >>](#)

Become a Registered Therapy Site

Become a Clinical Radiopharmaceutical Therapy Center of Excellence

Become a Comprehensive Radiopharmaceutical Therapy Center of Excellence

- ❖ Launched in February as a designation program
- ❖ Self-attestation
- ❖ A key component of the program is ongoing education in radiopharmaceutical therapy
- ❖ Addition of an accreditation level is being explored

Radiopharmaceutical Therapy Centers of Excellence

Applications received : 29

Approved Clinical sites:

- ❖ Christiana Care
- ❖ Excel Diagnostics and Nuclear Oncology Center

Approved Comprehensive sites:

- ❖ Stanford University - Stanford HealthCare
- ❖ Dana-Farber /Brigham and Women's Cancer Center
- ❖ Memorial Sloan Kettering Cancer Center
- ❖ SMM Health St. Louis University Hospital
- ❖ University of Minnesota Medical Center
- ❖ The Ohio State University Wexner Medical Center
- ❖ David Geffen School of Medicine at UCLA

Remaining applications are under review

RadioPharmaceutical Therapy Registry (RaPTR)



Facility and Treating Physician Information

Record ID: _____

Facility Information

Facility Type: ☐ Academic Medical Hospital/Center
☐ Community Hospital
☐ Veterans Affairs Hospital

Teaching Institution: ☐ Yes
☐ No

NCI Designated Center: ☐ Yes
☐ No
☐ Unknown

Zip Code of facility: _____

Physician Information

Specialty of Ordering Physician: ☐ Medical Oncologist
☐ Radiation Oncologist
☐ Surgical Oncologist
☐ Primary Care Physician
☐ Other

Please indicate the medical specialty:

Specialty of Treating Physician: ☐ Nuclear Medicine
☐ Diagnostic Radiologist
☐ Interventional Radiologist
☐ Radiation Oncologist
☐ Other

Does the radiologist have subspecialty training in nuclear medicine? ☐ Yes
☐ No

Please state the specialty: _____

Goal of RaPTR is to improve patient outcomes and promote patient safety of radiopharmaceutical therapies



⁶⁸Ga-Dotatate PET/CT scans



¹⁷⁷Lu-dotatate SPECT/CT scans

Lu177-dotatate (Lutathera)

- 4 pilot sites applying for IRB approval
- Clinical data collected in REDCap
- Imaging data including PET/CT, SPECT/CT, and planar via MIM Cloud

RaPTR Lite

- Clinical data only, no imaging data
- Will include Lu177-PSMA (Pluvicto) therapy

**Coming
Soon!**



Radiopharmaceutical Therapy Education for Technologists

JNMT Therapy – September 2022 Issue

- Focus on five therapies:
 - I-131
 - Xofigo
 - Lu-DOTA
 - Lu-PSMA
 - Azedra

Will include information on patient selection, clinical, technical, and regulatory considerations, protocols, radiation safety, dosimetry, imaging, billing, and coding and how to make the therapy a success.

JNMT
Journal of Nuclear Medicine Technology

Therapy Badging

- Comprehensive educational module for each therapy
- Upon completion of these modules, technologists will be awarded a “badge” which can be displayed on their curriculum vitae, LinkedIn or other social media and professional platforms.
- Proposed outline for each Therapy module:
 - Fundamentals
 - Patient Preparation
 - Therapy Administration
 - Post-Therapy
 - Radiation Safety
 - Billing and Coding
 - Dosimetry



New Awards

❖ One-year Research Therapy Fellowship (2 awardees)


- Sophia O'Brien, MD – University of Pennsylvania
- Ashwin Parihar, MD - Washington University School of Medicine



❖ Cancer Cooperative Group Mentorship Program (2021-2022 awardees)

- ECOG/ACRIN: **Liz Dibble**/Dave Mankoff & **Charles Marcus**/David Schuster
- Alliance: **Amir Iravani**/Tom Hope & **Courtney Lawhn-Heath**/Heather Jacene
- SWOG: **Erik Mittra**/Tony Shields
- NRG: **Dan Lee**/Dan Pryma

- 2022-2023 applicants under review currently



Radiopharmaceutical Therapy Trials



20 cm diameter certified tissue equivalent scatter/attenuation material phantom plus 250 ml sealable container for therapeutic radionuclide

SPECT/CT Calibration

To date, no one has developed an approach to validate the quantitative SPECT/CT image output, despite growing importance of dosimetry in radiopharmaceutical therapy.

SNMMI Clinical Trials Network is implementing a simple, reproducible radionuclide-specific SPECT/CT calibration approach for **clinical trials of radiopharmaceutical therapies** that include dosimetry.

Outreach

Presentations and Symposia

SNMMI provides presentations and satellite symposia at relevant medical societies to help healthcare providers better understand the role of nuclear medicine and molecular imaging in managing patients.

In 2021, SNMMI presentations included:

- **American Urology Association 2021 Annual Meeting**—PSMA imaging (272 attendees)
- **Pediatric Endocrine Society 2021 Annual Meeting**—Imaging endocrine disorders (260 attendees)
- **2021 San Antonio Breast Cancer Symposium**—Breast cancer imaging and diagnosis (54 attendees)
- **NANETS 2021 Annual Meeting**—Neuroendocrine tumor imaging and diagnosis (121 attendees)
- **ASTRO**—PSMA imaging (125 attendees)
- **Large Urology Group Practice Association**—PSMA imaging (151 attendees)

**SNMMI Mars Shot**

SNMMI has initiated the [Mars Shot Fund](#) with a goal of supporting innovative research in areas outlined in the Mars Shot for Molecular Imaging paper.

Next Steps: Developing a Roadmap to Approach Funders

Currently interviewing Mars Shot authors to identify specific Mars Shot-consistent, high-impact research projects, including relatable patient stories—to help make a compelling case to potential funders/investors.

Encourage and promote research in the field.



AI Summit

The AI Summit was held March 21-22. The summit convened stakeholders from FDA, NIH, academia, and industry including start-ups to device manufacturers, to discuss what is needed to advance AI and machine learning for nuclear medicine.

Four (4) Panels

- Academia, AI developers
- Industry
- End users, administrators, techs
- FDA, CMS, NIH, patients

Three (3) Lectures

- State of the Art of AI
 - Irene Buvat, PhD
- Role of Ethics in AI
 - Melissa McCradden, PhD
- Medical Imaging & Implementation Science
 - David Chambers, DPhil

Enhance research on how artificial intelligence, machine learning, and deep learning can be applied to nuclear medicine and molecular imaging.



Summit on Patient Access

Develop and organize resources to help hospitals implement theranostics, including guidelines on physical space, personnel, dose handling, dosimetry, patient discharge, etc.

The SNMMI Summit on Patient Access to Nuclear Medicine Procedures including Health Disparities was held March 22-23 and included speakers on a wide variety of access issues, ranging from disparities in healthcare to drug development and reimbursement.

Six (6) Panels (including FDA, NIH, CMS, payers)

- Health Disparities in Imaging: Lessons learned
- Federal Regulatory Efforts to ensure access to Nuclear Medicine
- Radiopharmaceutical production/distribution challenges, especially in rural America
- Foundational Infrastructure of Nuclear Medicine
- Appropriate utilization and reimbursement for services
- Payor Panel: What are you doing about access disparities in health?

Three (3) Lectures

- Global Access to Nuclear Medicine and Radiology – Lessons Learned from Lancet Oncology
 - Andrew Scott, MD
- Social Determinants of Health
 - Congressman Bobby Rush (invited)
- The Changing Landscape of Nuclear Medicine
 - Richard Barthel, MD




PR/Media: Educating the Public About the Benefits of Nuclear Medicine

- **UMBRELLA GOAL:** Utilize consumer media to increase awareness of nuclear medicine and promote research
- **Messaging for Consumer Media:**
 - **MESSAGE 1 – “PRECISE and EFFECTIVE”** – Nuclear medicine identifies the location of specific molecules within the body, allowing precise and effective diagnosis and treatment of disease
 - **MESSAGE 2 – “SAFE”** – Nuclear medicine procedures are among the safest diagnostic imaging exams available. Radiopharmaceutical therapy (RPT) is a safe treatment that has been successfully used for 80 years for cancers and hyperthyroidism
 - **MESSAGE 3 – “EXCEPTIONAL EXPECTATIONS”** – Nuclear medicine offers precise, tailored and painless diagnosis and treatment with minimal side effects and exceptional results for patients



PR/Media



- **Gaining traction in efforts to attract consumer media attention to nuclear medicine**
- **CBS TV (DC)/Get Up DC — Reaches 2.7 million**
 - Using Nuclear Medicine to Fight Diseases
 - Interview with Rich Wahl covering research arising out of SNMMI Annual Meeting
- **Fox 5 (Washington, DC) — Reaches 1.3 million**
 - Good Day DC morning program
 - How Nuclear Medicine Could Be a Game-Changer
 - 5-minute interview with Rich Wahl and Mike Crosby, a prostate cancer survivor



PR/Media: Patient Spotlight on Popular NYC Radio Show


Award-winning NYC 104.3 FM radio host, Shelli Sonstein of Sonstein Sundays interviews SNMMI patient advocate, Josh Mailman, and Dr. Richard Wahl – talking about how nuclear medicine helps Mailman successfully live with neuro-endocrine cancer for 15+ years.

- Posted on 104.3 FM NYC YouTube channel
- Featured on Sonstein Sessions podcast channel
- **COMING SOON:** Sonstein will do a "Part 2" follow-up with Dr. Wahl on "How nuclear medicine helps with non-cancer related disease"



PR/Media: Patients Spotlight Nuclear Medicine in Popular Magazine

 **AUTHORITY MAGAZINE**



"Nuclear medicine not only changed the path of my disease, but it also changed it for tens of thousands of those that have come after me."

I Survived Cancer and Here is How I Did It — Inspirational Stories Of People Who Beat Cancer — Reaches 125 million

Two patients submitted and chosen for interviews in this series in Authority Magazine and Thrive Global.

- **Josh Mailman** discussed how nuclear medicine helped diagnose and treat his neuroendocrine cancer
 - *Mailman interview chosen to be part of a book to be published on Amazon later this year.*
- **Theresa Wickerham** discussed how nuclear medicine helped diagnose and treat her thyroid cancer

 **THRIVE GLOBAL**




"Nuclear medicine diagnostics and therapies have made it easier to find and understand the cancer more precisely than we thought possible."



PR/Media: Women in STEM

- Dr. Helen Nadel in **Authority Magazine**, online consumer publication
- Dr. Nadel talks about her journey to becoming a **nuclear medicine** physician and how she can inspire other women in STEM fields
- **20 million reach**



PR/Media: Looking Ahead



Sharing patient stories and research utilizing as many different consumer media venues as possible (online, print, radio, TV, podcast)—to show **how nuclear medicine can improve quality and quantity of life**



We've done an excellent job of utilizing interesting patient stories and maintaining **consistent exposure**.



DC consumer media market exposure doubly beneficial because it **increases awareness in the federal government and regulatory agencies** that monitor access and affordability of nuclear medicine services.



More **regional media markets**—the San Francisco and LA markets look for local stories

SNMMI Value Initiative Domains

Quality of Practice

Research & Discovery

Workforce Pipeline & Lifelong
Learning

Outreach

Advocacy



Workforce Pipeline & Lifelong Learning

Ensuring SNMMI will continue to innovate and collaborate to retain and expand the diverse pool of qualified professionals working in the field, making the society the epicenter of all things related to nuclear medicine.



Workforce Pipeline & Lifelong Learning

2021-2022 Priorities

1

Ensure a sufficient # of professionals (physicians/scientists/technologists) qualified to practice all aspects of nuclear medicine/molecular imaging now and in the future.

2

Increase awareness of nuclear medicine/molecular imaging as an appealing and rewarding field for students interested in STEM (Science, Technology, Engineering and Mathematics) careers.

3

Increase recognition of SNMMI as the professional home of all nuclear medicine professionals irrespective of the training pathway.

How Will We Accomplish These Three Priorities?

Ensure a sufficient # of professionals (physicians/scientists/technologists) qualified to practice all aspects of nuclear medicine/molecular imaging now and in the future.

Survey & Data Collection – Understand the landscape of the NM/MI MD community

- ABNM Data – Backgrounds (& trends) of candidates sitting for Certification Exam and MOC
- NM RRC Data – Program & Resident trends over past 10-20 years
- Survey/Other Data Needed – NM Training, who is doing diagnostic NM/MI, Who is doing Therapy, what are current needs, what are future needs (including geographic)

Create/Implement **Three (3) NEW Pipeline Working Groups**

- Physician, Scientist, and Technologist

Host Nuclear Medicine/Nuclear Radiology **Program Director's Summit**

- Attendees: Representatives from NMPD, NM RRC, ABNM, APDR, NR RRC, ABR, Others?



Develop Educational Content/Curriculum for Residents

(1) radiopharmaceutical therapies and (2) diagnostic procedures.

Creating Working Group to begin development. Working Group to include representatives from:

Working Group to include:

- Residents (In-Training Committee and Early Career Professionals Committee)
- NM Program Directors
- ACGME NM RRC
- ABNM
- Other?



Increase awareness of nuclear medicine/molecular imaging as an appealing and rewarding field for students interested in STEM (Science, Technology, Engineering and Mathematics)

careers

Exhibits & Participation/Outreach

- Association of University Radiologists ([AUR](#)) – March 22-25, 2022 (Phoenix, AZ)
- American Medical Student Association ([AMSA](#)) – April 7-9, 2022 (Washington, DC)
- American Medical Association ([AMA](#)) – June 11-15, 2022 (Chicago, IL)



Medical Student and STEM Outreach Working Group

Includes individuals from the Women in Nuclear Medicine Committee; (2) Diversity, Equity and Inclusion Task Force; (3) Resident/In-Training Committee; (4) Early Career Professionals Committee; and (5) NM Program Directors

- Creation of NM Pathway [Ambassadors Program](#)
- [Pairing Research Projects](#) w/ Medical Students, Residents, Fellows
- Communicating with Medical Students via #MedTwitter; #TipsForNewDocs; The Student Doctor Network (website)



SNMMI Value Initiative Domains

Quality of Practice


Research & Discovery

Workforce Pipeline & Lifelong Learning

Outreach

Advocacy





Outreach

2021-2022 Priorities

1

Increase the number of patients advocating in support of the value of radiopharmaceuticals.

2

Increase referring physicians' awareness of the value of nuclear medicine and molecular imaging, with particular emphasis on new radiopharmaceuticals.

3

Improve collaboration with other medical societies.

Patient Advocacy Advisory Board (PAAB)

SNMMI collaborates with 14 patient advocacy organizations to develop patient-specific programs.

- **Advocacy:** PAAB members participate in SNMMI Hill Days and Virtual Fly-ins and sign on to letters of support for nuclear medicine access issues.
- **Education:** More than 1,000 patients and caregivers have viewed SNMMI's 2021 Virtual Patient Education Day program. We had excellent engagement, with 51 questions submitted during the live event.

It makes a difference! We ask patients: *"On a scale of 1 to 5, how safe do you believe NM and MI procedures are?"*

- Before Patient Education Day: Score = 3.34
- **After Patient Education Day: Score = 4.34**

#ReturnToCare Coalition

- SNMMI spearheaded this campaign to encourage patients to seek timely screenings, scans, vaccinations, and treatments during the pandemic.
- The coalition comprises a broad spectrum of **30 member organizations**, including patient groups and medical societies.



Increase the number of patients advocating in support of the value of radiopharmaceuticals.



Increase referring physicians' awareness of the value of nuclear medicine and molecular imaging, with particular emphasis on new radiopharmaceuticals.

HCP Roadshows (Virtual and In Person)

SNMMI provides both in-person and virtual education for healthcare providers on disease-specific topics. Among the events held in 2021 and planned for 2022:

- Three webinars on lymph node mapping and sentinel node biopsy (355 total attendance)
- Two webinars on treatment of pheo/para, presented in conjunction with NANETS (160 total attendance)
- New series of in-person roadshows on prostate cancer imaging and diagnosis launching April 2022

Improve collaboration with other societies.

Presentations and Symposia

SNMMI provides presentations and satellite symposia at relevant medical societies to help healthcare providers better understand the role of nuclear medicine and molecular imaging in managing patients.

In 2021, SNMMI presentations included:

- **American Urology Association 2021 Annual Meeting**—PSMA imaging (272 attendees)
- **Pediatric Endocrine Society 2021 Annual Meeting**—Imaging endocrine disorders (260 attendees)
- **2021 San Antonio Breast Cancer Symposium**—Breast cancer imaging and diagnosis (54 attendees)
- **NANETS 2021 Annual Meeting**—Neuroendocrine tumor imaging and diagnosis (121 attendees)
- **ASTRO**—PSMA imaging (125 attendees)
- **Large Urology Group Practice Association**—PSMA imaging (151 attendees)



SNMMI Value Initiative Domains

Quality of Practice

Research & Discovery

Workforce Pipeline & Lifelong Learning

Outreach

Advocacy



Advocacy

Promoting awareness among policymakers about the NM/MI field. Paramount in this area is cooperative work with other organizations and outreach with regulatory agencies and the legislature to advocate for a better approval, coverage and reimbursement process for NM/MI drugs, devices, diagnostic procedures, and therapies.



Advocacy

2022 Priorities

1

Ensure adequate and appropriate coverage & reimbursement for NM/MI procedures.

2

Improve the FDA's understanding to approve RPs as "safe and effective" and CMS's determination that they are "reasonable and necessary."

3

Enhance state-level advocacy

4

Address U.S. pharmacopeia compounding issues

5

Increase visibility with federal legislators

6

Seek improvements in the integrity of the isotope supply chain and components





■ Private Payers

Writing letters and holding meetings for **coverage** of NM drugs and procedures including RPs for NETs and prostate cancer detection

Ensure adequate and appropriate coverage & reimbursement for NM/MI procedures.

■ Medicare

- **Submitted comments and met with CMS** on the NCD for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's
- Responded to CMS's Interim Final Rule on **Surprise Billing**
- **Educating MACs** on the removal of the exclusionary language for non-oncologic PET and PSMA PET



Improve the FDA's understanding to approve RPs as "safe and effective" and CMS's determination that they are "reasonable and necessary."

- Working with R&D to **expand access** to RP ANDAs for non-proprietary radiopharmaceuticals.
- Responded to FDA's notice re: Genus, advocating for all RPs to be labeled as drugs

Improve the FDA's understanding to approve RPs as "safe and effective" and CMS's determination that they are "reasonable and necessary."

- Working with R&D to **expand access** to RP ANDAs for non-proprietary radiopharmaceuticals.
- Responded to FDA's notice re: Genus, advocating for all RPs to be labeled as drugs

Enhance state level advocacy

Supporting NM Technologists

- Coordinating with ARRT, ASRT, and other societies on various NM technologist [state licensure initiatives](#).
- Working to elevate the profession of the NMT through legislative action by [supporting baccalaureate programs](#) and opposing earn-and-learn programs that jeopardize accreditation/certification/licensure.



Address U.S. pharmacopeia compounding issues.



USP

- Q&As from membership re: USP<825> are now [posted](#) on our website
- Developing [SOPs](#) for USP <825>
- Submitted comments regarding <797> revisions

Increase visibility with federal legislators

Increasing Visibility

- Supporting federal research funding opportunities
- Conducting virtual fly-ins for the FIND Act and extravasation education
- Participating/hosting Hill briefings and webinars for the FIND Act
- Launched various letter-writing campaigns, wrote letters of support for legislation, and assisted with Dear Colleague letters.



SNMMI Value Initiative
SOCIETY OF NUCLEAR MEDICINE & MOLECULAR IMAGING

Facilitating Innovative Nuclear Diagnostics (FIND) Act

Nuclear medicine scans are often the most effective **AND** cost-effective way to diagnose certain diseases, providing the best possible care for patients, **but...**

Patients lack access to nuclear medicine scans that could **change the course of their treatment**.

Physicians are less likely to administer a game-changing PET or other nuclear medicine scan because of **lack of appropriate reimbursement**.

Hospitals are facing the decision of **discontinuing certain nuclear medicine procedures**, because Medicare does not cover anywhere near full drug cost.

Companies that have innovated life-changing nuclear medicine drugs are **having trouble keeping them in production and developing new ones**.

Medicare is **paying for unnecessary therapies, surgery, and hospital stays** because it continues to treat these drugs as supplies and bundles them in with the scan.

The bi-partisan **Facilitating Innovative Nuclear Diagnostics (FIND) Act** will ensure patient access to these imaging procedures.

Ensure Patient Access to Innovative Diagnostic Imaging Drugs

Cosponsor H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021

As conditions such as Alzheimer's and Parkinson's disease, advanced cardiac disease, and cancers of the prostate, breast and brain continue to exact a heavy toll on elderly Americans, **Medicare's current reimbursement structure limits patient access to innovative imaging tools that improve diagnosis of these deadly diseases.**

CONGRESS CAN INCREASE MEDICARE BENEFICIARY ACCESS TO ADVANCED DIAGNOSTIC IMAGING BY PASSING H.R. 4479/S. 2609, THE FACILITATING INNOVATIVE NUCLEAR DIAGNOSTICS (FIND) ACT



- Keeping the website updated with [isotope supply](#) information

- Responded to the DOE's RFI on the [supply of Mo-99](#) produced without the use of HEU

Seek improvements in the integrity of the isotope supply chain and components.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PLUVICTO safely and effectively. See full prescribing information for PLUVICTO.

PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use

Initial U.S. Approval: 2022

-----**INDICATIONS AND USAGE**-----

PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. (1)

-----**DOSAGE AND ADMINISTRATION**-----

- Select patients for treatment using LOCAMETZ® or an approved PSMA-11 imaging agent based on PSMA expression in tumors. (2.2)

Other Initiatives/Programs

Other Initiatives/Programs

EDITORIAL

At Last, ^{18}F -FDG for Inflammation and Infection!

Richard L. Wahl¹, Vasken Dilsizian², and Christopher J. Palestro³

¹School of Medicine, Washington University in St. Louis, St. Louis, Missouri; ²University of Maryland School of Medicine, Baltimore, Maryland; and ³Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York

1048 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 62 • No. 8 • August 2021

Radiopharmaceutical Supply



Current and resolved drug shortages and discontinuations reported to FDA are found [here](#). Below, please find shortages and other isotope supply news reported by our members and industry partners. If you have specific questions about shortages and would like to connect with other members, please visit [SNMMI Connect](#).

February 10, 2022

A communication from the NMEU Emergency Response Team (ERT) announced the resumption of IRE HEU Mo-99 and I-131 operations. All IRE technical operations have been completed. The release of the first batch of HEU-based Mo-99 is planned for February 17 and HEU-based I-131 for February 28. [Read the full notice here](#).

February 08, 2022

Radiopharmaceutical Tc99m Kit Supply Update

Sun Radiopharma is experiencing a supply interruption for several radiopharmaceutical products. In order to successfully re-enter the market, their current strategy is to continuously manufacture one product at a time until sufficient inventory is obtained. The most critical product, Sulfur Colloid, re-entered the market on **January 11, 2022**. The next anticipated lot release date is noted below. Lots will continue to be released over the next few months. [Read the full notice here](#).

Product Release Schedule

1. Sulfur Colloid: February 18, 2022
2. Mebrofenin: April 15, 2022
3. Mertiatide: April 21, 2022
4. Pyrophosphate: May 9, 2022
5. Sestamibi: June 14, 2022
6. Medronate: June 30, 2022

NRC Rulemaking 10 CFR Part 35

The NRC has approved initiating rulemaking to modernize 10 CFR Part 35 to address rubidium-82 generators, GSR units, Y-90 microspheres and emerging medical technologies. <http://ow.ly/WYRa30s9XJF>
 #NuclearMedicine #SNMMI



- The Nuclear Regulatory Commission (NRC) recently voted on [training and experience requirements \(T&E\) for Authorized Users \(AUs\)](#) and disapproved their staff's recommendations. SNMMI strongly supports this long-awaited decision.
- Current pathways for obtaining AU status are:
 - Certification by a medical specialty board whose certificate is recognized by the NRC or an Agreement State (e.g., ABNM)
 - Completion of 200 hours of classroom training and 500 hours of supervised work experience in an ACGME-accredited program (i.e., Nuclear Medicine, Diagnostic Radiology with a 16-month NM/NR pathway, or Radiation Oncology)
 - Previous identification as an AU on an NRC or Agreement State license or permit



NEW - Quality and Patient Safety

Mission: Ensure that the members of SNMMI provide high quality care to their patients during examination and treatments they perform.

The committee will identify top issues and address each area for vigilance and continued improvement

- Survey of nuclear medicine practices to inform the efforts of the group
 - Delivery of radiopharmaceuticals
 - Develop/revise policy on extravasation, including documentation of scope of extravasation
 - Quality of injections
 - Improve and standardize injection techniques
 - Develop statement on quality of injections on the website
 - Communication
 - Qualifications of nuclear medicine personnel
 - Patient falls
 - Emerging areas in RPT therapy
 - Image Quality
- Work Group on Quality and Safety of FDA Inspections (Co-chairs; Drs. Ghesani and Cutler)

2022 SNMMI Annual Meeting – Vancouver, BC, Canada



Safety Protocols

At this time, the SNMMI 2022 Annual Meeting is scheduled to be held as a hybrid event, both in person in Vancouver, BC, Canada, as well as virtually. We will continue to monitor the ongoing conditions in British Columbia and across the world, and communicate any changes to the meeting should they arise.

Please note: SNMMI is committed to ensuring that appropriate and necessary health and safety protocols will be in place for this event. We will follow all Centers for Disease Control and Prevention (CDC) safety protocols and recommendations and will comply with all federal, state and local regulations. **Attendees must be fully vaccinated for COVID-19 and masks will be required.**

➔ www.snmmi.org/AM2022

2022 SNMMI Annual Meeting – Vancouver, BC, Canada

	Complete Meeting Package (In-Person Attendance) includes:	In-Person Registration includes:
In Person Attendance	<ul style="list-style-type: none"> Name Badge that offers access to all in-person educational sessions*, Exhibitor Welcome Reception and Poster Hall Live Streamed Sessions to watch virtually from your hotel room or other convenient location and On-Demand Sessions for 30 days (available within 48 hours after the completion of the live session) Access to meeting recordings for three (3) years in the SNMMI Learning Center with CE available for select sessions <p><small>*Pre-Meeting Categorical Seminars and Specialty Workshops are NOT included in the Full Registration Fee but may be purchased individually.</small></p>	<ul style="list-style-type: none"> Name Badge that offers access to all in-person educational sessions**, Exhibitor Welcome Reception and Poster Hall Live Streamed Sessions to watch virtually from your hotel room or other convenient location and On-Demand Sessions for 30 days (available within 48 hours after the completion of the live session) <p><small>**Pre-Meeting Categorical Seminars and Specialty Workshops are NOT included in the Full Registration Fee but may be purchased individually. Does <u>not</u> include the additional 3-year access to the CE Sessions in the SNMMI Learning Center.</small></p>
	Complete Meeting Package (Remote Attendance) includes:	Remote Access (only) Registration includes:
Remote Attendance	<ul style="list-style-type: none"> Live Streamed Sessions to watch virtually from the convenience of your home or office Access to All On-Demand Sessions for 30 days (available within 48 hours after the completion of the live session) Access to meeting recordings for three (3) years in the SNMMI Learning Center with CE available for select sessions <p><small>*Pre-Meeting Categorical Seminars and Specialty Workshops are NOT available for remote attendees. Does not include a Name Badge and does not provide access to Meeting Rooms or Events in Vancouver.</small></p>	<ul style="list-style-type: none"> Live Streamed Sessions to watch virtually from the convenience of your home or office Access to All On-Demand Sessions for 30 days* (available within 48 hours after the completion of the live session) <p><small>*Pre-Meeting Categorical Seminars and Specialty Workshops are NOT available for remote attendees. Does not include a Name Badge and does not provide access to Meeting Rooms or Events in Vancouver. Does <u>not</u> include the additional 3-year access to the CE Sessions in the SNMMI Learning Center.</small></p>

Department of Energy Grant

SNMMI in June 2020 received a \$750,000 three-year grant from the Department of Energy's National Nuclear Security Administration to increase nuclear medicine capacity in sub-Saharan Africa.

- Partnering with Korle Bu Teaching Hospital in Accra, Ghana
- Providing education (primarily virtual to date)
- Purchasing equipment to allow them to expand their radiology department's PACS system and to help them with their goal to begin doing cardiac procedures



International Collaboration

WFNMB

- Members of the WFNMB Governing Council
- Participating in a strategic committee to look at structure and function of WFNMB

EANM

- Collaborative SNMMI Procedure Standards/EANM Practice Guidelines
- Sessions at SNMMI Annual Meeting and EANM Annual Congress

MOU's signed with the following organizations:

- European Association of Nuclear Medicine (EANM)
- Korean Society of Nuclear Medicine (KSNM)
- Japanese Society of Nuclear Medicine (JSNM)
- India Society of Nuclear Medicine (India SNM)

IAEA

- Webinars about the latest techniques and developments in nuclear medicine and molecular imaging (offered in Spanish and English).
- Generous support of IAEA - livestream the 2019 Annual Meeting to IAEA Member States.
- Speakers and Leadership representation at IAEA meetings.
- Free registration to the SNMMI annual meeting for select young investigators.
- Representation and collaboration on guidance documents and positions.
- Support the virtual 2020 meeting.

International Collaboration

Nuclear Medicine Global Initiative



- To encourage global collaboration in education; to harmonize procedure guidelines and other policies or to improve quality and safety.
- Organizations involved:
 - Nuclear medicine societies – China, Japan, Korea, India, Australia/New Zealand, Canada, South Africa
 - Multinational organizations – EANM, IAEA, WFNMB, ALASBINM, AOFNMB
- Projects
 - 1st Project—Standardization of Administered Activities in Pediatric Nuclear Medicine
 - 2nd Project—Availability of Radiopharmaceuticals
 - 3rd Project—Theranostics: an evidence-based NM value as the third topic

KEY SNMMI Membership Benefits

NEW in 2021 SNMMI Launches NEW Career Center



- **New Career Center Launched in 2021**
- Featured jobs appear on SNMMI homepage.
- Members can create job alerts (which will be e-mailed DIRECTLY to you).
- Members can search the company directory to find jobs where they want to work.




Webinar Website

SNMMI launched a new webinar portal to better support an **increased focus** on virtual learning opportunities.

This new portal provides **simplified** navigation, options to register for multiple events at once, easier **access** to content details, and links to both **live** and **on-demand** webinars.

www.snmmi.org/webinars

****NEW**** - When you register for a webinar, you receive a **confirmation e-mail** with the link for the **webinar** AND option to **add to your calendar**!



Welcome to the SNMMI Webinars Hub

[View Upcoming Webinars](#)

Upcoming Webinars

[All Webinars](#) [Industry Webinars](#)

Date	Time (ET)	Webinar Title	Details
2/17/2022	7:00-8:00 PM	Black History Month Inclusive Gathering	Details
2/22/2022	12:00-1:00 PM	Pediatric PET: High Yield Uses and Opportunities	Details
3/8/2022	12:00-1:00 PM	Brief Review and Tips on Some of the Aspects of the Business	Details
3/8/2022	1:00-2:00 PM	Renal Functional Cortical Imaging with Tc-99m DMSA	Details
3/15/2022	12:00-1:00 PM	Fluciclovine PET/CT for Prostate Cancer	Details
4/19/2022	12:00-1:00 PM	ER Targeted PET with 18F-Fluoroestradiol	Details
5/17/2022	12:00-1:00 PM	PET/MR: Where Can My Patients Benefit?	Details
7/19/2022	12:00-1:00 PM	Cardiac Amyloid and Sarcoid: Tips for Reading like an Expert	Details
8/16/2022	12:00-1:00 PM	Lung Nodules on PET/CT: Mastering the Proper Work-Up	Details
9/20/2022	12:00-1:00 PM	NET Therapeutics: Only the Beginning	Details
10/18/2022	12:00-1:00 PM	Dementia Imaging: Rapidly Growing Use in Nuclear Medicine	Details
11/15/2022	12:00-1:00 PM	Head & Neck: Critical Anatomy for PET/CT	Details
12/20/2022	12:00-1:00 PM	Sodium Fluoride PET: Mastering Normal and Abnormal	Details
12/20/2022	12:00-1:00 PM	Sodium Fluoride PET: Mastering Normal and Abnormal	Details

Easy Access to St...
Providing leading nuclear medicine a access this cutting-edge content who support needed to advance your care

Keeping You Certified

Continuing Education


You can earn all the CE credits you need in one place with free registration to quarterly, live webinars, and access to years of on-demand educational programs. Credit programs are available in the SNMMI Learning Center, including online journal exams from the JNM and JNMT.

Manage Your VOICE credit

SNMMI-TS provides the ARRT and NMTCB reports of members who have participated in SNMMI-TS education activities upon request. Enroll in the VOICE Credit Sharing program by logging on to the SNMMI website.

VOICE Program

SNMMI-TS members receive automatic enrollment in the computerized continuing education accounting system, VOICE. Members will receive an annual computerized transcript during their birth month of any submitted credit forms.



www.snmmi.org/education

SNMMI Solutions

Exclusive Resources:

- **Coding Corner:** The most up-to-date and comprehensive source for NM coding and reimbursement information on the web
- **Coding Q&A:** Ask the coding experts your questions online, and filter by specific parameters
- **Nuclear Medicine Radiation Dose Tool:** Specify the procedure, the injected activity, and the patient model
- **Reader Training:** Education and training opportunities for the new FDA approved radiotracers and therapeutic agents
- **Clinical Guidelines**
 - Appropriate Use Criteria (AUC)
 - Scope of Practice
 - Procedure Standards
 - Dose Optimization

Coding and Reimbursement Q&A

To find what you need, filter questions by subject and setting. Filter Results...

Select Subject(s) of Interest: Select Setting(s) of Interest:

-- All --
Cardiac
Endocrine
Gastrointestinal
General
Genitourinary

-- All --
Hospital
Physician Office & IDTFs

Search

Practice Resources

A center for raising awareness of standards and initiatives.

- PET PROGS
- Credentialing
- Practice Accreditation
- Image Gently
- Image Wisely
- Scope of Practice
- Webinars
- Journal Articles

It's our top priority to be your primary resource

Stay Connected



Like the SNMMI Facebook Page at
www.facebook.com/mysnmimi



Follow [@SNM_MI](https://twitter.com/SNM_MI) on Twitter



Join the SNMMI LinkedIn Group by
searching [Society of Nuclear
Medicine and Molecular Imaging](#)



Subscribe to [SNMChannel1](#) on YouTube



Follow [SNM_MI](#) on Instagram



Thank You
SNMMI MEMBERS



**We hope to
SEE you
again
soon...**

STAY SAFE!